Get to know our clinical trials
AZD0305 trial in participants with multiple myeloma.
THE PURPOSE OF THIS TRIAL IS TO LEARN WHETHER THE TRIAL DRUG WILL BE SAFE, TOLERABLE AND EFFECTIVE IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA AND ALSO TO BETTER UNDERSTAND THE DISEASE BEING STUDIED AND THE ASSOCIATED HEALTH PROBLEMS.
Technical Summary
- AN UNBLINDED, MODULAR PHASE I/II TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF AZD0305 IN PARTICIPANTS WITH MULTIPLE MYELOMA.
- Code EudraCT: 2023-508590-89
- Protocol number: D7230C00001
- Promoter: AstraZeneca Farmacéutica Spain
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.